Symposium
[Free Online Symposium] Cardiac Safety from Preclinical to the Clinic: Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks
Speakers:
Borje Darpo (ERT), Jay Mason (Spaulding Clinical), Anne Bonneville (Terns Pharmaceuticals), Lauren Lohmer (Nuventra), Yehong Wang (Genentech)
Organizers:
Peter Staehr (ChemoCentryx), Snow Ge (Nektar), Kelly Gelinne (Nuventra) and Ginny Schmith (Nuventra)
Date:
2021-03-23- 03/24/2021
Time:
8:30-12:30 Pacific Time
Registration fee:
(USD):
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-03-20
(it will close sooner if the seating cap is reached)
About the Topic
In an effort to reduce risk to patients, regulatory agencies now require rigorous analysis of QT intervals in clinical trials as a measure of drug safety. This seminar will discuss the various ways to evaluate cardiac safety using a variety of methods - as early as preclinical and throughout your clinical trials.
Symposium Agenda – Day 1: March 23, 2021 (Times listed for Pacific Time (PT) and Eastern Time (ET))
8:30-8:45 PT / 11:30-11:45 ET: PBSS Welcome and Introductions – Shichang Miao, PBSS President
8:45-9:30 PT / 11:45-12:30 ET: State-of-the-Art: TQT studies (QT and C-QT Analyses, Challenges & Examples) - Borje Darpo (ERT)
9:30-10:15 PT / 12:30-1:15 ET: Non-clinical aspects related to the ICH Q&A - Anne Bonneville (Terns Pharmaceuticals)
10:15-10:25 PT / 1:15-1:25 ET: AltaSciences – Major Sponsor Presentation
10:25-10:40 PT / 1:25-1:40 ET: Break
10:40-11:25 PT / 1:40-2:25 ET: Case Study - Biologics C-QT project supporting a major readout - Yehong Wang (Genentech)
11:25 -12:10 PT / 2:25-3:10 ET: Panel Discussion Day 1 (All speakers, moderated by Ginny Schmith)
Symposium Agenda – Day 2: March 24, 2021 (Times listed for Pacific Time (PT) and Eastern Time (ET))
8:30-8:45 PT / 11:30-11:45 ET: Introductions
8:45-9:30 PT / 11:45-12:30 ET: Cardiac safety and TQT waivers (Waiver pathways, ECG acquisition requirements) - Jay Mason (Spaulding)
9:30-10:15 PT / 12:30-1:15 ET: Wide Confidence Intervals with a Non-Positive Concentration-Related Slope: Implications from the White Paper - Lauren Lohmer (Nuventra)
10:15-10:30 PT / 1:15-1:30 ET: Break
10:30-11:15 PT / 1:30-2:15 ET: Evaluating QT Changes in the Presence of HR Changes - Lars Johannesen (FDA)
11:15 -12:00 PT / 2:15-3:00 ET: Panel Discussion Day 2 (All speakers except Yehong Wang, moderated by Ginny Schmith)
About the SpeakersClick to Enter Answer Explanations.
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|